Eric Crombez is VP at Ultragenyx Pharmaceutical Inc. (RARE). They have made 9 open-market trades across 2 companies since 2024, most recently 2026-05-15.
CIK 0001653052
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RARE | 111,189 | $1.6M |
| ABEO | 37,313 | $166K |
| Total | $1.8M |
Shares reported on the most recent Form 4, priced at the 2026-05-15 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABEO | SELL · 10b5-1 | 2026-05-15 | 2026-05-15 | $5.53 | $145K | +5.3% | +3.3% | +15.3% |
| RARE | SELL | 2026-05-05 | 2026-05-06 | $24.96 | $9K | -5.4% | -14.3% | +1.1% |
| RARE | SELL | 2026-03-02 | 2026-03-03 | $22.80 | $160K | -3.3% | +1.7% | +3.6% |
| ABEO | SELL | 2026-02-02 | 2026-02-02 | $5.09 | $83K | -3.5% | -3.9% | +15.0% |
| ABEO | SELL | 2025-08-14 | 2025-08-15 | $6.93 | $33K | -3.0% | -19.5% | -36.3% |
| RARE | SELL | 2025-04-21 | 2025-05-05 | $37.93 | $29K | -8.3% | -3.7% | -25.1% |
| RARE | SELL | 2025-03-03 | 2025-03-04 | $42.10 | $753K | -4.0% | -14.3% | -11.9% |
| RARE | SELL | 2024-05-02 | 2024-05-03 | $43.66 | $15K | -3.9% | -3.8% | +3.2% |
| RARE | SELL | 2024-04-18 | 2024-04-19 | $44.10 | $6K | +0.2% | -3.9% | -1.0% |
| RARE | SELL | 2024-03-01 | 2024-03-05 | $53.76 | $133K | -7.9% | -8.4% | -20.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.